ETF DAILY NEWS

D. Boral Capital Initiates Coverage on Plus Therapeutics (NASDAQ:PSTV)

D. Boral Capital began coverage on shares of Plus Therapeutics (NASDAQ:PSTV – Free Report) in a research note released on Monday, MarketBeat.com reports. The firm issued a buy rating and a $9.00 target price on the stock. A number of other research firms have also recently weighed in on PSTV. Ascendiant Capital Markets decreased their […]

Mar 18, 2025 - 06:57
 0
D. Boral Capital Initiates Coverage on Plus Therapeutics (NASDAQ:PSTV)
D. Boral Capital began coverage on shares of Plus Therapeutics (NASDAQ:PSTV – Free Report) in a research note released on Monday, MarketBeat.com reports. The firm issued a buy rating and a $9.00 target price on the stock. A number of other research firms have also recently weighed in on PSTV. Ascendiant Capital Markets decreased their […]
Read More

Tags:

Previous Article

Veritone (NASDAQ:VERI) Earns Buy Rating from Analysts at LADENBURG THALM/SH SH

Next Article

Chardan Capital Reaffirms Buy Rating for Avidity Biosciences (NASDAQ:RNA)

Related Posts

Dexterra Group (TSE:DXT) Given New C$11.50 Price Target at National Bankshares

Dexterra Group (TSE:DXT) Given New C$11.50 Price Target...

Feb 28, 2025  0

Promising Outdoor Stocks To Follow Now – February 16th

Promising Outdoor Stocks To Follow Now – February 16th

Feb 18, 2025  0

Direxion Daily AAPL Bull 2X Shares (NASDAQ:AAPU) Sees Large Increase in Short Interest

Direxion Daily AAPL Bull 2X Shares (NASDAQ:AAPU) Sees L...

Mar 5, 2025  0